Mount Sinai Kravis Children's Hospital

Winners of the American Liver Foundation 2023 Liver Health Poster Competition Announced

Retrieved on: 
Wednesday, May 10, 2023
Linda, Volunteering, Duke University, Fatty liver disease, ALF, Liver disease, People's Choice Awards, American Liver Foundation, Saint Louis University, Liver transplantation, Liver cancer, Patient, Mount Sinai Kravis Children's Hospital, Duke University School of Medicine, Diagnosis, Poster, Hospital, Empathy, Indonesian Choice Awards, Caregiver, Loyola University Medical Center, Dietary supplement, Medical device, Dentistry, Nursing, Food delivery, Houston Methodist Hospital, Pediatrics, MD

FAIRFIELD, N.J., May 10, 2023 /PRNewswire/ -- Winners from the American Liver Foundation's 2023 Liver Health Poster Competition were announced today. This competition showcases posters and a brief video created by early career healthcare professionals from across the country on six areas of liver educational focus: disparities in liver disease, fatty liver disease, liver cancer, liver transplantation, pediatric liver disease, and rare liver disease. Competitors are tasked with translating complicated medical information into a poster and video which can be easily understood by patients or the public.

Key Points: 
  • FAIRFIELD, N.J., May 10, 2023 /PRNewswire/ -- Winners from the American Liver Foundation 's 2023 Liver Health Poster Competition were announced today.
  • This competition showcases posters and a brief video created by early career healthcare professionals from across the country on six areas of liver educational focus: disparities in liver disease , fatty liver disease , liver cancer , liver transplantation , pediatric liver disease , and rare liver disease .
  • The 2023 Liver Health Poster Competition category winners are:
    Tanisha Ronnie, MD, Loyola University Medical Center for her presentation on liver disparities .
  • To learn more about the 2023 Liver Health Poster Competition or view all the submissions, visit: alfevents.org/poster-competition .

Smart Glass Technologies Implements PriWatt Switchable Privacy Smart Glass for Mount Sinai Kravis Children's Hospital

Retrieved on: 
Wednesday, February 1, 2023
Hygiene, Mount Sinai Kravis Children's Hospital, SGT, Glass, Patient, Hospital, Environment, Paola Lattus, Privacy, Television, Medicine

Miami, Florida--(Newsfile Corp. - February 1, 2023) - Smart Glass Technologies™ (SGT) implements PriWatt switchable privacy smart glass for Mount Sinai Kravis Children's Hospital.

Key Points: 
  • Miami, Florida--(Newsfile Corp. - February 1, 2023) - Smart Glass Technologies™ (SGT) implements PriWatt switchable privacy smart glass for Mount Sinai Kravis Children's Hospital.
  • To view an enhanced version of this graphic, please visit:
    Smart Glass Technologies LLC was contracted by the glazing contractor to manufacture the PriWatt switchable privacy smart glass in various areas of the hospital.
  • The implementation of PriWatt switchable privacy smart glass provides a number of benefits for the hospital, including:
    Improved patient privacy: The ability to switch the glass from clear to opaque allows for privacy during medical procedures and consultations.
  • The implementation of PriWatt switchable privacy smart glass by Smart Glass Technologies LLC is a valuable addition to the renovation project at Mount Sinai Kravis Children's Hospital.

Mount Sinai Beth Israel Recognized by the American College of Surgeons National Surgical Quality Improvement Program for Meritorious Outcomes in Surgical Patient Care

Retrieved on: 
Wednesday, November 9, 2022
No, Fellowship of the Royal Colleges of Surgeons, College, Mount Sinai Hospital, Patient, MS, Hospital, ACS, YouTube, Mount Sinai Health System, Program, Journal of Neurology, Neurosurgery, and Psychiatry, National, Icahn School of Medicine at Mount Sinai, News, Urology, American College of Surgeons, NEW, U.S. News & World Report, Health, Mount Sinai Hospital (Manhattan), Knowledge, FACS, Surgeon, Nursing, U.S. News & World Report Best Hospitals Rankings, MSHS, American College, National Institutes of Health, SSI, Informatics, Health system, School, Artificial intelligence, Physician, Rehabilitation, Community, Mount Sinai Kravis Children's Hospital, Mount Sinai Beth Israel, Health care, Dentistry, Medicine, MD, Ophthalmology, Newsweek, Research, Facebook, Orthopedic surgery, Geriatrics

NEW YORK, Nov. 9, 2022 /PRNewswire-PRWeb/ -- The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) has recognized Mount Sinai Beth Israel for achieving meritorious outcomes for surgical patient care in 2021. Mount Sinai Beth Israel is one of 78 hospitals to achieve this honor out of an eligible 607 hospitals that participate in the program.

Key Points: 
  • The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) has recognized Mount Sinai Beth Israel for achieving meritorious outcomes for surgical patient care in 2021.
  • NEW YORK, Nov. 9, 2022 /PRNewswire-PRWeb/ -- The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) has recognized Mount Sinai Beth Israel for achieving meritorious outcomes for surgical patient care in 2021.
  • Mount Sinai Beth Israel is one of 78 hospitals to achieve this honor out of an eligible 607 hospitals that participate in the program.
  • These results inform patient safety initiatives within the hospital and impact the quality of surgical care for all patients.

MindMaze Partners with Mount Sinai Health System to Pioneer a Digital Neurotherapeutic Program to Improve Patient Outcomes in the Clinic and at Home

Retrieved on: 
Tuesday, November 8, 2022
Neurology, Software, Hardware, Health, Artificial Intelligence, Hospitals, Health Technology, Technology, U.S. News & World Report, Neuroscience, Brain, School, Program, National, Stroke, Health, Mount Sinai Hospital (Manhattan), National Institutes of Health, Journal of Neurology, Neurosurgery, and Psychiatry, Solution, Rehabilitation, Informatics, Encarta, Community, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, U.S. News & World Report Best Hospitals Rankings, Disability, Hospital, Partnership, Mount Sinai Health System, Concussion, Health system, Technology, Engineering, Artificial intelligence, Annals of Neurology, Knowledge, News, Physician, Neurology, Patient, No, Nursing, Survivor, Mount Sinai Kravis Children's Hospital, Disease, Urology, Research, Pharmaceutical industry, Geriatrics, Newsweek, Medicine, Ophthalmology, Orthopedic surgery

MindMaze develops digital neurotherapeutic solutions designed to elevate outcome expectations today and to accelerate the future of cognitive recovery and care.

Key Points: 
  • MindMaze develops digital neurotherapeutic solutions designed to elevate outcome expectations today and to accelerate the future of cognitive recovery and care.
  • Data from the program will inform the Mount Sinai medical registry, with results supporting clinical effectiveness, scalability, and viability of the initiative.
  • MindMaze and Mount Sinai are passionate about providing stroke survivors with ever improving access to care and re-defining the possibilities with neuro-recovery.
  • Founded in 2012, MindMaze is a global leader in brain technology and digital neurotherapeutic solutions for brain health and recovery.

Maze Therapeutics Appoints Harold Bernstein, M.D., Ph.D., as President, Research and Development and Chief Medical Officer

Retrieved on: 
Thursday, October 13, 2022
Health, Genetics, Other Health, Research, Science, Pharmaceutical, Biotechnology, Pompe, LinkedIn, Merck, CSO, Medicine, Glycogen storage disease type II, Therapy, Chronic kidney disease, Head, BioMarin Pharmaceutical, Science, Mount Sinai Kravis Children's Hospital, ALS Therapy Development Institute, Cardiology, Vertex, Harvard College, Patient, Twitter, Research, HIV disease progression rates, Internal medicine, History, Precision medicine, Technology, R, University, Industry, Mount Sinai School, Pediatrics, UCSF Benioff Children's Hospital, Icahn School of Medicine at Mount Sinai, Genetics, University of California, San Francisco, Stanford University, Third Rock Ventures, Bristol Myers Squibb, Systems biology, Gene, Data science, UCSF, Management, Pharmaceutical industry, Maze, Brigham, Compass

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Harold Bernstein, M.D., Ph.D., a 30-year industry veteran, has been appointed as president, head of research and development (R&D) and chief medical officer.

Key Points: 
  • Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Harold Bernstein, M.D., Ph.D., a 30-year industry veteran, has been appointed as president, head of research and development (R&D) and chief medical officer.
  • In addition, Eric Green, M.D., Ph.D., who has served as Mazes senior vice president, research and translational sciences, has been promoted to chief scientific officer.
  • Dr. Bernstein brings more than three decades of experience in basic scientific research, translational medicine and clinical development both in industry and academia.
  • He joins Maze from BioMarin, where he served as senior vice president, chief medical officer and head of global clinical development.

Mount Sinai Researchers Report Encouraging Immunotherapy Option for Relapsed Myeloma Patients

Retrieved on: 
Thursday, September 1, 2022
Icahn School of Medicine at Mount Sinai, National Cancer Institute, Artificial intelligence, News, Mount Sinai Hospital, Informatics, U.S. News & World Report Best Hospitals Rankings, U.S. News & World Report, NEW, Urology, Twitter, Rehabilitation, Patient, Survival, Antigen, Nursing, Hospital, Mount Sinai Hospital (Manhattan), Newsweek, World, Translational research, Health system, CAR, Community, Multiple myeloma, Journal of Neurology, Neurosurgery, and Psychiatry, MD, School, NCI, Mount Sinai Kravis Children's Hospital, Health, YouTube, Monoclonal antibody, Physician, Salvage therapy, No, National, National Institutes of Health, Genomics, Sinai, Mount Sinai Health System, Knowledge, Clinical trial, Vaccine, Pharmaceutical industry, Medicine, Facebook, Geriatrics, Medicine, Ophthalmology, Orthopedic surgery

NEW YORK, Sept. 1, 2022 /PRNewswire-PRWeb/ -- Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails. Bispecific antibodies are a type of antibody that can bind to two different antigens at the same time—they are meant to enhance the immune system's destruction of tumor cells.

Key Points: 
  • Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails.
  • NEW YORK, Sept. 1, 2022 /PRNewswire-PRWeb/ -- Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails.
  • In the August 26 online edition of Blood Advances , Mount Sinai researchers report that sequential use of different T-cell redirection therapies in these multiple myeloma patients is possible and could lead to good patient outcomes and survival.
  • In a retrospective analysis, researchers identified 58 multiple myeloma patients who participated in a bispecific antibodies clinical trial at Mount Sinai and underwent salvage therapy due to relapse.

Scientists Discover Gene Mutation That Signals Aggressive Melanoma

Retrieved on: 
Thursday, April 7, 2022
NEW, National Cancer Institute, No, Rehabilitation, Research, Color, Mount Sinai Hospital, Hospital, Chromatin, Neoplasm, Journal of Neurology, Neurosurgery, and Psychiatry, Skin cancer, Twitter, U.S. News & World Report, Community, Mount Sinai Hospital (Manhattan), Health system, Disease, Mutation, Urology, Mount Sinai Health System, Health, Cell Reports, Brain, Honors student, National, DNA, Gene expression, Melanoma, Doctor of Philosophy, World, Mount Sinai Kravis Children's Hospital, Patient, Cell, Skin, News, Icahn School of Medicine at Mount Sinai, National Institutes of Health, Purdue University, National Cancer Center, Physician, YouTube, Newsweek, Vaccine, Medical imaging, Geriatrics, New York University, Medicine, ARID2, Orthopedic surgery, Ophthalmology, Facebook

NEW YORK, April 7, 2022 /PRNewswire-PRWeb/ -- Mutation of a gene called ARID2 plays a role in increasing the chance that melanoma, a deadly skin cancer, will turn dangerously metastatic, Mount Sinai researchers report.

Key Points: 
  • Mutation of a gene called ARID2 plays a role in increasing the chance that melanoma, a deadly skin cancer, will turn dangerously metastatic, Mount Sinai researchers report.
  • NEW YORK, April 7, 2022 /PRNewswire-PRWeb/ -- Mutation of a gene called ARID2 plays a role in increasing the chance that melanoma, a deadly skin cancer, will turn dangerously metastatic, Mount Sinai researchers report.
  • The findings suggest that patients whose melanoma tumors have an ARID2 mutation may have a more aggressive cancer and may need to be treated differently, according to a study published in Cell Reports in April.
  • In this study, scientists used melanoma tumor models to measure the role of the ARID2 gene in cancer progression.

SandboxAQ and Mount Sinai Health System Collaborate on Data Protection

Retrieved on: 
Wednesday, March 23, 2022
Post-quantum cryptography, PALO, NIST, Information technology, Sandbox, Alphabet Inc., Icahn School of Medicine at Mount Sinai, No, National Institute of Standards and Technology, Urology, Rehabilitation, Pulmonology, Software as a service, News, Division, Mount Sinai Health System, Health system, Hospital, Mount Sinai Hospital, U.S. News & World Report, National Institute, World, CEO, National Institutes of Health, Health, Journal of Neurology, Neurosurgery, and Psychiatry, Ophthalmology, Twitter, PQC, National, Mount Sinai Kravis Children's Hospital, Mount Sinai Hospital (Manhattan), Physician, Solution, YouTube, Newsweek, AI, Quantum, Patient, Medical device, Medicine, Medicine, Geriatrics, Gastroenterology, Orthopedic surgery, Facebook, Technology

NEW YORK and PALO ALTO, Calif., March 23, 2022 /PRNewswire/ -- Sandbox AQ, an enterprise SaaS company leveraging quantum tech and AI, announced today a collaboration with Mount Sinai Health System to launch Post-Quantum Cryptography (PQC) solutions, a broad security technology solution to protect patient data against current and future cybersecurity threats.

Key Points: 
  • Through Sandbox AQ, Mount Sinai Health System will incorporate PQC protocols into its network to provide increased security for millions of customers and their sensitive data.
  • "Our collaboration with Sandbox AQ propels our security and technology strategies forward, enabling us to deliver advanced, secure cutting-edge products to our patients," said Kristin Myers, Executive Vice President and Chief Information Officer at Mount Sinai Health System and Dean for Information Technology at Icahn School of Medicine at Mount Sinai.
  • The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region.
  • 1 in New York and top five globally, and Mount Sinai Morningside as top 20 globally, and "The World's Best Specialized Hospitals" ranks Mount Sinai Heart as No.

Phillips School of Nursing Launches Innovative Tuition-Free Program to Advance Nurses With Associate's Degrees to Bachelor's Degrees

Retrieved on: 
Tuesday, February 1, 2022
CCNE, Mount Sinai Kravis Children's Hospital, Mount Sinai Health System, Physician, Twitter, National League, Newsweek, Phillips School, Honors student, Time, MSN, Commissioner, DNP, PSON, Rehabilitation, Program, National League for Nursing, Nursing, Health, World, RN, Health system, Mount Sinai Beth Israel, U.S. News & World Report, Hospital, Icahn School of Medicine at Mount Sinai, National, Phillips School of Nursing at Mount Sinai Beth Israel, Student, Journal of Neurology, Neurosurgery, and Psychiatry, National Institutes of Health, Mount Sinai Hospital (Manhattan), No, News, YouTube, APRN, Mount Sinai Hospital, Center, Urology, School, Science, Washington Assessment of Student Learning, BSN, Critical care, Community, Medicine, Ophthalmology, Orthopedic surgery, Geriatrics, Autumn, Education, Facebook, Medicine

I am not aware of any other health system that has partnered with a school of nursing to offer a program like this."

Key Points: 
  • I am not aware of any other health system that has partnered with a school of nursing to offer a program like this."
  • Nurses hired for the program will work and train in cohorts at each of the eight hospitals in the Mount Sinai Health System.
  • New nurses hired and current Mount Sinai nurses with associate's degrees who enroll, will join one of three semesters (Spring, Summer and Fall) that will be offered annually.
  • During the program, participants will function as registered nurses 80 percent of the time with the remaining 20 percent devoted to paid study time.

PreciseDx Raises $10.75 Million Series A Preferred from Healthcare Industry Leaders to Commercialize Cancer Risk Stratification Services to Support Better Patient Insights and Outcomes

Retrieved on: 
Tuesday, January 11, 2022
Research, Division, Mount Sinai Health System, Intelligence, Urology, Hospital, Mount Sinai Hospital, Cancer, Journal of Neurology, Neurosurgery, and Psychiatry, Ophthalmology, Technology, Wheaton Industries, Death, Icahn School of Medicine at Mount Sinai, No, Oncology, Digital health, Agilent Technologies, Company, Doctor of Philosophy, BD (company), Multimedia, Mount Sinai Kravis Children's Hospital, Patient, Health, U.S. News & World Report, Mount Sinai Hospital (Manhattan), World, Recurrence, National, News, GHI, Investment, Marie Cassidy, Rehabilitation, National Institutes of Health, Breast cancer, Digital, HIV disease progression rates, Health system, YouTube, Attention, Pathology, Twitter, Newsweek, Physician, Pharmaceutical industry, Medical imaging, Geriatrics, Merck, Orthopedic surgery, Facebook, Medicine, Gastroenterology

Leveraging AI insights and data derived from high-volume, well-annotated study populations, PreciseDx offers breast cancer diagnostic test services, with a prostate cancer test in development.

Key Points: 
  • Leveraging AI insights and data derived from high-volume, well-annotated study populations, PreciseDx offers breast cancer diagnostic test services, with a prostate cancer test in development.
  • The use of morphology features to stratify cancer risk provides valuable insights into cancer treatment, attracting the attention of healthcare innovators.
  • The funding will be used to support the development and commercialization of additional cancer diagnostics and clinical trial testing.
  • PreciseDx was established to improve the quality of cancer treatment for all patients through our risk stratification platform.